6.02
-0.26(-4.14%)
Currency In USD
| Previous Close | 6.28 |
| Open | 6.27 |
| Day High | 6.43 |
| Day Low | 6 |
| 52-Week High | 6.95 |
| 52-Week Low | 2.95 |
| Volume | 150,379 |
| Average Volume | 218,172 |
| Market Cap | 352.66M |
| PE | -5.28 |
| EPS | -1.14 |
| Moving Average 50 Days | 4.92 |
| Moving Average 200 Days | 4.74 |
| Change | -0.26 |
If you invested $1000 in Foghorn Therapeutics Inc. (FHTX) since IPO date, it would be worth $332.23 as of January 18, 2026 at a share price of $6.02. Whereas If you bought $1000 worth of Foghorn Therapeutics Inc. (FHTX) shares 5 years ago, it would be worth $312.4 as of January 18, 2026 at a share price of $6.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
GlobeNewswire Inc.
Jan 13, 2026 9:05 PM GMT
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today anno
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
GlobeNewswire Inc.
Jan 10, 2026 3:20 AM GMT
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) adva
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today anno